(Q42795506)

English

Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient

scientific article published on November 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

immunosuppression

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J Signorell

1

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

T Hunziker

2

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

M Martinelli

3

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

S C Koestner

4

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

P J Mohacsi

5

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

3871-3875

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Skin cancers after organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Malignancy following kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Three-year follow-up of malignancies in tacrolimus-treated renal recipients--an analysis of European multicentre studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Cancer after kidney transplantation in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Influence of immunosuppression on the prevalence of cancer after kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Cancer incidence and survival in kidney transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

De novo tumors after liver transplantation: a single-institution experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Incidence and clinical course of de-novo malignancies in renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

A Prospective Study of Incident Nonmelanoma Skin Cancer in Heart Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Non-melanoma skin cancer and its risk factors in an Austrian population of heart transplant recipients receiving induction therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

The incidence of immunosuppression-related skin disease in long-term transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Premalignant and malignant skin lesions in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Cancer, warts, and sunshine in renal transplant patients. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Incidence of skin cancer after renal transplantation in The Netherlands.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

High incidence and clinical course of aggressive skin cancer in heart transplant patients: a single-center study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Immunosuppressive level and other risk factors for basal cell carcinoma and squamous cell carcinoma in heart transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Azathioprine and UVA light generate mutagenic oxidative DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Everolimus and reduced cyclosporine trough levels in maintenance heart transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Sirolimus for Kaposi's sarcoma in renal-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Regression of Kaposi's sarcoma in renal graft recipients after conversion to sirolimus treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Multidisciplinary insights on clinical guidance for the use of proliferation signal inhibitors in heart transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Conversion to everolimus in a patient with arterial hypertension and recurrent cutaneous neoplasia--a case report

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Malignancy after heart transplantation: incidence, prognosis and risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2010.07.090

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2010.07.090

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

release_ukzk2ilauvduteiwkt2kcq6qt4

1 reference

https://api.fatcat.wiki/v0/release/ukzk2ilauvduteiwkt2kcq6qt4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42795506&oldid=1970574831"